Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ent of metastatic breast cancer and is also in Phase 2 studies for the treatment of lung and brain cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. Additional late-stage development products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting rFVIII program, which is in Phase 3 clinical development for patients with hemophilia A.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com

*Sources: Bell TJ et. al. Pain Med 2009;10(1):35-42, Hess B et. al. Eur J Intern Med 2011;22(5):527-531, Rosti G et. al Eur Rev Med Pharmacol Sci. 2010;14(12):1045-1050. Galvez R et. al. Aten Primaria 2014;46(1):32-39, Droney J et. al. Support Care Cancer 2008;16(5):453-459.

Movantik is a trademark of AstraZeneca.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential regulatory approval of Movantik&
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
(Date:8/27/2015)... 27, 2015  A recent study by Feucht ... compared the Arthrosurface HemiCAP® Wave implant, which is ... "onlay" design implant for isolated patellofemoral disease. While ... and pain scores, none of the patients in ... However, 53% of the patients in the "onlay" ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Oct. 12 Today at the annual AdvaMed ... provider of Good Promotional Practices software, announced a ... hotline and case management solutions. Together, the companies ... to help Life Sciences companies cope with the ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... general business update on Monday, October 12, 2009, at 8:00 ... parties may access a live webcast of the presentation on ... or by dialing 847-413-3362 and using the passcode 25577870#. ...
Cached Medicine Technology:Prolifiq and EthicsPoint Announce Partnership: 'Automatic Alerts' Help Life Sciences Engage in Good Promotional Practices 2Prolifiq and EthicsPoint Announce Partnership: 'Automatic Alerts' Help Life Sciences Engage in Good Promotional Practices 3
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... 2015 , ... Dr. Tim Novelli, DC., Founder and President of the Patriot ... of the chiropractic field in the military. All too often VA hospitals treat patients ... made available to the VA program over a decade ago, the reality is that ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Should physicians be banned from assisting in a lethal ... A recent ruling by the American Board of Anesthesiology ... punishment, and other medical boards may act similarly. An ... concludes that decertification of physicians participating in lethal ...
... HealthDay Reporter , THURSDAY, June 9 (HealthDay News) ... disease among kidney patients by as much as 25 percent, ... ever conducted. "People with kidney disease are at a ... Dr. Colin Baigent, a professor of epidemiology at the University ...
... in the Clinical Neuropsychologist (e-publication ahead of ... in the brain development of preschool children with symptoms ... the brain important for cognitive and motor control was ... Novel for its use of neuroimaging in very young, ...
... Sheffield,s School of Health and Related Research (ScHARR) has developed ... been accepted for use by the Department of Health. ... Jacques and James Fotheringham, were commissioned in January 2011 by ... index to look at deaths following a hospital admission. In ...
... , Bethesda, MD Vaccinating children around the world against ... past several decades. Now new opportunities exist to overcome remaining ... according articles in the June 2011 edition of Health ... from the Bill & Melinda Gates Foundation. Last ...
... into a wallet or pursebut it could mean the difference between ... stores personal medical data (e.g. information on existing medical conditions, allergies ... enabling the data to be accessed in just a few moments. ... have been trialled in the UK. This working prototype has ...
Cached Medicine News:Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 3Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 2Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 3Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:New hospital mortality rate index to be used across UK 2Health News:New hospital mortality rate index to be used across UK 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 2Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 4Health News:MyCare -- the 'card' that could save your life 2
... knee system was designed to ... between all articulating surfaces and ... with wear in order to ... with normalized quadriceps and patellar ...
...
...
...
Medicine Products: